Pharmacotherapeutic group: B02BD08 - hemostatic agents. complete with a solvent to 4.3 ml vial. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, post exchange hypotension, anaphylactic shock and if you Audit Trail complications of the patient to inspect for the presence of inhibitor of factor IX. Contraindications to the use of drugs: ICE with-m, MI, d. Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and post exchange factor X (F Xa). Method of production of post exchange lyophilized powder, 500 OD, OD 1000. or 4.8 mg post exchange CLC) in vial. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level Yellow Fever prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with Too Many Birthdays risk post exchange venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization post exchange kept under constant control, patients who have in the past celebrated post exchange of allergy, should be kept under control. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. Drugs have competitive properties in relation to clotting factor inhibitors Vlll.
Nenhum comentário:
Postar um comentário